Physician profile
Gerardo Negron
NPI 1396795795
$2,022.74
in general payments reported to CMS, 2019-2025
13 companies · $43.16 in 2025
The $43.16 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $366 · 2021: $300 · 2022: $248 · 2023: $349 · 2024: $135 · 2025: $43.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.65 |
| Education | $121.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $495.61 | 2019-2024 | Cresemba |
| Insmed, INC. | $475.13 | 2020-2025 | Arikayce |
| Janssen Biotech, INC. | $296.56 | 2019-2023 | Symtuza |
| Melinta Therapeutics, LLC | $205.04 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $169.47 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $76.94 | 2022-2024 | Nuzyra |
| Pfizer INC. | $74.84 | 2023-2025 | |
| Theratechnologies INC. | $69.94 | 2023-2024 | Trogarzo, Egrifta |
| Janssen Products, Lp | $65.00 | 2021 | |
| Mayne Pharma Commercial LLC | $39.88 | 2020-2022 | |
| Viiv Healthcare Company | $26.01 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $16.05 | 2020 | |
| Shionogi INC | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Negron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.